Scinai Immunotherapeutics (SCNI) director discloses major share and RSU stake

Rhea-AI Filing Summary

Scinai Immunotherapeutics Ltd. director Uri Ben-Or filed an initial ownership report showing substantial equity holdings. He directly beneficially owns 33,329,004 Ordinary Shares, including several large restricted share unit (RSU) grants that vest over multiple years, subject to his continued service. These include 4,425,004 Ordinary Shares in RSUs granted on January 25, 2024, 904,000 Ordinary Shares in RSUs granted on November 21, 2024, and 28,000,000 Ordinary Shares in RSUs granted on November 12, 2025, each with specified multi-year vesting schedules. He also holds 630 American Depositary Shares, which are convertible at any time into 2,519,344 Ordinary Shares with no expiration date.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Ben-Or Uri

Role Director

Type	Security	Shares	Price	Value
holding	American Depositary Shares	--	--	--
holding	Ordinary shares, no par value per share ("Ordinary Shares")	--	--	--

Holdings After Transaction: American Depositary Shares — 2,519,344 shares (Direct); Ordinary shares, no par value per share ("Ordinary Shares") — 33,329,004 shares (Direct)

Footnotes (1)

1. The Ordinary Shares are represented by American Depositary Shares, each of which currently represents four thousand Ordinary Shares. Includes 4,425,004 Ordinary Shares that are represented by restricted share units ("RSUs") that were granted on January 25, 2024, of which 25% vested on the six-month anniversary thereof, 8.33% vested on the 12-month anniversary thereof, and 66.66% vest in two equal annual installments thereafter, subject to the Reporting Person's continued service through such dates. Each RSU represents a contingent right to receive one Ordinary Share upon vesting. Includes 904,000 Ordinary Shares that are represented by RSUs that were granted on November 21, 2024, which vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through such dates Includes 28,000,000 Ordinary Shares that are represented by RSUs that were granted on November 12, 2025, which vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through such dates. Represents 630 American Depositary Shares, which are convertible at any time into 2,519,344 Ordinary Shares, at the holder's election and have no expiration date.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Ben-Or Uri

(Last) (First) (Middle)

C/O SCINAI IMMUNOTHERAPEUTICS LTD.

JERUSALEM BIOPARK, 2ND FLOOR

(Street)

JERUSALEM 9112002

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Scinai Immunotherapeutics Ltd. [ SCNI ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares, no par value per share ("Ordinary Shares")(1)	33,329,004(2)(3)(4)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
American Depositary Shares	(5)	(5)	Ordinary Shares	2,519,344	(5)	D

Explanation of Responses:

1. The Ordinary Shares are represented by American Depositary Shares, each of which currently represents four thousand Ordinary Shares.

2. Includes 4,425,004 Ordinary Shares that are represented by restricted share units ("RSUs") that were granted on January 25, 2024, of which 25% vested on the six-month anniversary thereof, 8.33% vested on the 12-month anniversary thereof, and 66.66% vest in two equal annual installments thereafter, subject to the Reporting Person's continued service through such dates. Each RSU represents a contingent right to receive one Ordinary Share upon vesting.

3. Includes 904,000 Ordinary Shares that are represented by RSUs that were granted on November 21, 2024, which vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through such dates

4. Includes 28,000,000 Ordinary Shares that are represented by RSUs that were granted on November 12, 2025, which vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through such dates.

5. Represents 630 American Depositary Shares, which are convertible at any time into 2,519,344 Ordinary Shares, at the holder's election and have no expiration date.

Remarks:

Exhibit 24 - Power of Attorney.

	/s/ Uri Ben-Or	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Uri Ben-Or’s Form 3 for Scinai Immunotherapeutics (SCNI) show?

The Form 3 shows that director Uri Ben-Or has a large beneficial equity position in Scinai Immunotherapeutics. It details his direct holdings of Ordinary Shares, major RSU grants with multi-year vesting, and American Depositary Shares convertible into additional Ordinary Shares.

How many Ordinary Shares does Uri Ben-Or report owning in SCNI on this Form 3?

He reports beneficial ownership of 33,329,004 Ordinary Shares. This total includes shares underlying several restricted share unit grants with different vesting schedules, as well as Ordinary Shares represented by his American Depositary Shares position, all held directly.

What RSU grants are disclosed for Uri Ben-Or in Scinai Immunotherapeutics (SCNI)?

The filing discloses RSUs for 4,425,004 Ordinary Shares granted January 25, 2024, 904,000 Ordinary Shares granted November 21, 2024, and 28,000,000 Ordinary Shares granted November 12, 2025. Each grant vests in installments over several years, contingent on continued service.

How do Uri Ben-Or’s RSUs in SCNI vest over time?

The 4,425,004-share RSU grant vests 25% at six months, 8.33% at twelve months, and 66.66% in two equal annual installments. The 904,000 and 28,000,000-share grants each vest in three equal annual installments, all subject to his continued service on those dates.

What American Depositary Share (ADS) holdings does Uri Ben-Or report for SCNI?

He reports holding 630 American Depositary Shares. According to the disclosure, these ADS are convertible at any time into 2,519,344 Ordinary Shares at the holder’s election. They have no expiration date, providing ongoing flexibility to convert into Ordinary Shares.

Does this Scinai Immunotherapeutics (SCNI) Form 3 show Uri Ben-Or buying or selling shares?

No buy or sell transactions are reported; it is an initial ownership statement. The entries are classified as holdings, listing his existing Ordinary Shares, RSUs, and American Depositary Shares rather than documenting new purchases or sales on the reported date.